Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17474368 | 0.93 | DRD2 (0.41) | DRD2HTR2AHTR7HTR6KCNK2 | |
| SCHEMBL17482018 | 0.82 | KCNK2 (0.33) | KCNK2PIM1 | |
| SCHEMBL17482024 | 0.81 | KCNK2 (0.42) | KCNK2MEN1KMT2AMAPT | |
| SCHEMBL17474401 | 0.76 | KCNK2 (0.46) | KCNK2MEN1KMT2AMAPT | |
| SCHEMBL8739572 | 0.76 | DRD2 (0.48) | DRD2HTR2AHTR7HTR6DRD3 | |
| SCHEMBL17482052 | 0.76 | KCNK2 (0.48) | KCNK2MAPT | |
| SCHEMBL17474429 | 0.75 | KDM1A (0.46) | DRD2HTR2AHTR7HTR6DRD3 | |
| SCHEMBL17482017 | 0.73 | PLK1 (0.31) | — | |
| SCHEMBL17482021 | 0.72 | KCNK2 (0.44) | KCNK2MEN1KMT2AMAPT | |
| SCHEMBL17484599 | 0.71 | KCNK2 (0.53) | KCNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9862684-B2 | Modulation of K2P channels | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-01-09 | — | — | US | disclosed |
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031814-A1 | MODULATION OF K2P CHANNELS | KCNJ2, KCNK2, KCNN3 | DRD2 879/4885HTR2A 156/4885HTR7 397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.